Примери за използване на Consisting of genetically modified на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Kymriah contains the active substance tisagenlecleucel(consisting of genetically modified white blood cells).
The vaccine consisting of genetically modified recombinant Stx2e stimulates an active immunity against Shiga toxin 2e produced by the causative agent of oedema disease in pigs.
Yescarta contains the active substance axicabtagene ciloleucel(consisting of genetically modified white blood cells).
Where the application concerns a veterinary medicinal product containing or consisting of genetically modified organisms within the meaning of Article 2 of Directive 2001/18/EC of the European Parliament and of the Council[24] the application shall in addition to the documents listed in paragraph 1 be accompanied by.
Environmental risk assessments for medicinal products containing, or consisting of, genetically modified organisms(GMOs).
In the case of a veterinary medicinal product containing or consisting of genetically modified organisms, the opinion of the said Committee must respect the environmental safety requirements laid down by Directive 2001/18/EC.
Articles 13 to 24 of Directive 2001/18/EC shall not apply to veterinary medicinal products containing or consisting of genetically modified organisms.
In the case of a veterinary medicinal product containing or consisting of genetically modified organisms within the meaning of Article 2 of Directive 2001/18/EC, the application shall also be accompanied by.
Articles 13 to 24 of Directive 2001/18/EC shall not apply to medicinal products for human use containing or consisting of genetically modified organisms.
In the case of a medicinal product for human use containing or consisting of genetically modified organisms within the meaning of Article 2 of Directive 2001/18/EC, the application shall be accompanied by.
Whereas Articles 10 to 18 of Directive 90/220/EEC lay down a Community procedure enabling the competent authority of a Member State to give consent to the placing on the market of products containing, or consisting of, genetically modified organisms;
In the case of a veterinary medicinal product containing or consisting of genetically modified organisms, the opinion of the said Committee must respect the environmental safety requirements laid down by Directive 2001/18/EC.
Having regard to the draft Commission implementing decision amending Implementing Decision 2013/327/EU as regards the renewal of the authorisation to place on the market feed containing or consisting of genetically modified oilseed rapes Ms8, Rf3 and Ms8× Rf3 pursuant to Regulation(EC) No 1829/2003 of the European Parliament and of the Council(D059688/02).
During evaluation of requests for the placing on the market of products containing or consisting of genetically modified organisms, the necessary consultations shall be held by the Commission or the Member States with the bodies set up by the Community or the Member States in accordance with Directive 90/220/EEC.
The application also covered the placing on the market of products containing or consisting of genetically modified maize Bt11× MIR162× 1507× GA21 for uses other than food and feed, with the exception of cultivation.
Whereas the application also covered the placing on the market of products containing or consisting of genetically modified maize MON 87427× MON 89034× 1507× MON 88017× 59122 for uses other than food and feed, with the exception of cultivation;
During the process of evaluating applications for marketing authorizations for products containing or consisting of genetically modified organisms, necessary consultations will be held by the rapporteur with the bodies set up the Community or the Member States in accordance with Directive 90/220/EEC.
During the process of evaluating applications for marketing authorisations for veterinary medicinal products containing or consisting of genetically modified organisms, necessary consultations shall be held by the rapporteur with the bodies set up by the Community or the Member States in accordance with Directive 2001/18/EC.
During the process of evaluating applications for marketing authorisations for medicinal products for human use containing or consisting of genetically modified organisms, the rapporteur shall carry out necessary consultations of bodies that the►M8 Union◄ or Member States have set up in accordance with Directive 2001/18/EC.
During the process of evaluating applications for marketing authorisations for veterinary medicinal products containing or consisting of genetically modified organisms, necessary consultations shall be held by the rapporteur with the bodies set up by the►M8 Union◄ or the Member States in accordance with Directive 2001/18/EC.
In the case of genetically modified plants for food or feed uses, food orfeed containing or consisting of genetically modified plants and food produced from or containing ingredients produced from genetically modified plants or feed produced from genetically modified plants, in point 3.1.C.
During the process of assessing applications for marketing authorisations for veterinary medicinal products containing or consisting of genetically modified organisms as referred to in Article 7(5), the necessary consultations shall be held by the Agency with the bodies set up by the Union or Member States in accordance with Directive 2001/18/EC.
Contains or consists of genetically modified organisms;
Zalmoxis is prepared from human blood of a specific donor and it consists of genetically modified cells.
Articles 11 to 18 of Directive 90/220/EECshall not apply to foods or food ingredients which contain or consist of genetically modified organisms.
Regulation(EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed(8) provides for an authorisation procedure for the placing on the market of genetically modified food and feed, including feed additives consisting of, containing or produced from genetically modified organisms.
Gene therapy medicinal product containing genetically modified cells The finished medicinal product shall consist of genetically modified cells formulated in the final immediate container for the intended medical use.
Part 2 applies to products consisting of or containing genetically modified higher plants.
Products containing, consisting of, or produced from genetically modified maizes.
Part 1 applies to products consisting of or containing genetically modified organisms other than higher plants and contains the following sections.